Your shopping cart is currently empty

LY-2584702 tosylate salt, a selective ATP-competitive p70S6K inhibitor, is being used in clinical trials for cancer treatment.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $31 | In Stock | In Stock | |
| 2 mg | $44 | In Stock | In Stock | |
| 5 mg | $72 | In Stock | In Stock | |
| 10 mg | $122 | In Stock | In Stock | |
| 25 mg | $228 | In Stock | In Stock | |
| 50 mg | $378 | In Stock | In Stock | |
| 100 mg | $538 | In Stock | In Stock | |
| 500 mg | $1,150 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $97 | In Stock | In Stock |
| Description | LY-2584702 tosylate salt, a selective ATP-competitive p70S6K inhibitor, is being used in clinical trials for cancer treatment. |
| Targets&IC50 | p70 S6K:4 nM |
| In vitro | In HCT116 colon cancer cells, LY2584702 inhibits phosphorylation of the S6 ribosomal protein (pS6) with IC50 of 0.1-0.24 μM. [1] LY2584702 has significant synergistic effects when combined with EGFR inhibitor erlotinib or with the mTOR inhibitor everolimus. [2] |
| In vivo | LY2584702 (12.5 mg/kg BID), demonstrates significant antitumor efficacy in both U87 mg glioblastoma and HCT116 colon carcinoma xenograft models. [1] |
| Synonyms | LY2584702 tosylate |
| Molecular Weight | 617.62 |
| Formula | C28H27F4N7O3S |
| Cas No. | 1082949-68-5 |
| Smiles | Cc1ccc(cc1)S(O)(=O)=O.Cn1cc(nc1C1CCN(CC1)c1ncnc2[nH]ncc12)-c1ccc(F)c(c1)C(F)(F)F |
| Relative Density. | no data available |
| Storage | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||
| Solubility Information | Ethanol: < 1 mg/mL (insoluble or slightly soluble) DMSO: 12 mg/mL (19.43 mM), Sonication is recommended. | ||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 1 mg/mL (1.62 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||
DMSO
| |||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.